公开(公告)号：US20240207307A1

公开(公告)日：2024-06-27

申请号：US18555323

申请日：2022-04-13

申请人： FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ,  FUNDACIÓ INSTITUT CATALÀ DE NANOCIÈNCIA I NANOTECNOLOGIA (ICN2) ,  INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS

发明人： Víctor Franco Puntes ,  Eudald Casals Mercadal ,  Miguel Angel Zapata Victori ,  Anna Salas Torras ,  Anna Duarri Piqué ,  Anna Badia Pérez ,  Josep García Arumí

IPC分类号： A61K33/244 ,  A61K9/00 ,  A61K9/14 ,  A61P27/06 ,  B82Y5/00

CPC分类号： A61K33/244 ,  A61K9/0048 ,  A61K9/145 ,  A61P27/06 ,  B82Y5/00

摘要： A colloidal suspension of single crystal cerium oxide nanoparticles for use in the treatment of a disorder or disease of the posterior segment of the eye by administering a topical ophthalmic dose of the colloidal suspension.

公开(公告)号：US11944639B2

公开(公告)日：2024-04-02

申请号：US17073026

申请日：2020-10-16

申请人： OXYMO TECHNOLOGIES INC.

发明人： Rémi Wilmotte ,  Frédéric Lorenzo ,  Denis Olivier Chretien

IPC分类号： A61K33/24 ,  A61K9/00 ,  A61K9/08 ,  A61K33/242 ,  A61K33/244 ,  A61K33/40 ,  A61K47/08 ,  A61K47/18 ,  A61P31/22

CPC分类号： A61K33/24 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/0048 ,  A61K9/006 ,  A61K9/08 ,  A61K33/242 ,  A61K33/244 ,  A61K33/40 ,  A61K47/08 ,  A61K47/183 ,  A61P31/22 ,  A61K33/24 ,  A61K2300/00 ,  A61K33/40 ,  A61K2300/00

摘要： The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising: —at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (V), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; —at least one chelating agent; —at least one source of peroxidative radicals; —at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.

公开(公告)号：US20230263786A1

公开(公告)日：2023-08-24

申请号：US18001917

申请日：2021-06-17

申请人： Akebia Therapeutics, Inc. ,  Mitsubishi Tanabe Pharma Corporation

发明人： Ajit CHAVAN ,  Rishikesh SAWANT ,  Yoshimasa KOKADO ,  Takehiro NANJO ,  Shuji KINOSHITA ,  Naomi KONISHI

IPC分类号： A61K31/4418 ,  A61K33/06 ,  A61K33/244 ,  A61K33/26 ,  A61K31/366 ,  A61K31/47 ,  A61K31/405 ,  A61K31/22 ,  A61K31/505 ,  A61K31/40

CPC分类号： A61K31/4418 ,  A61K33/06 ,  A61K33/244 ,  A61K33/26 ,  A61K31/366 ,  A61K31/47 ,  A61K31/405 ,  A61K31/22 ,  A61K31/505 ,  A61K31/40

摘要： Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.

公开(公告)号：US20230102115A1

公开(公告)日：2023-03-30

申请号：US18053609

申请日：2022-11-08

申请人： OXYMO TECHNOLOGIES INC.

发明人： Rémi WILMOTTE ,  Frédéric LORENZO ,  Denis Olivier CHRETIEN

IPC分类号： A61K33/24 ,  A61K9/00 ,  A61K47/18 ,  A61K9/08 ,  A61K33/40 ,  A61K47/08 ,  A61K33/242 ,  A61K33/244 ,  A61P31/22

摘要： The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising:at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (W), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; at least one chelating agent; at least one source of peroxidative radicals; at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.

公开(公告)号：US20220386619A1

公开(公告)日：2022-12-08

申请号：US17878652

申请日：2022-08-01

申请人： EVOQ NANO, INC.

发明人： William Harold Niedermeyer

IPC分类号： A01N59/16 ,  A61K33/24 ,  A61K33/242 ,  A61K33/244 ,  A61K33/243

摘要： Antimicrobial compositions for killing or deactivating microbes, such as viruses, bacteria, or fungi, include metal nanoparticles, a carrier, and a plurality of metal nanoparticles. The nanoparticles can be selected to have a particle size and particle size distribution to selectively and preferentially kill one of a virus, a bacterium, or a fungus. Antiviral compositions can include nanoparticles having a particle size of 8 nm or less, 1-7 nm, 2-6.5 nm, or 3-6 nm. Antibacterial compositions can include nanoparticles having a particle size of 3-14 nm, 5-13 nm, 7-12 nm, or 8-10 nm. Antifungal compositions can include nanoparticles having a particle size of 9-20 nm, 10-18 nm, 11-16 nm, or 12-15 nm.

公开(公告)号：US11406662B2

公开(公告)日：2022-08-09

申请号：US16850468

申请日：2020-04-16

申请人： ZS PHARMA, INC.

发明人： Donald Jeffrey Keyser ,  Alvaro F. Guillem

IPC分类号： A61K33/24 ,  B01J39/14 ,  B01J39/02 ,  C01B39/00 ,  A61K9/14 ,  A61K33/00 ,  A61K45/06 ,  C01B33/20 ,  B01J19/00 ,  B01J19/18 ,  A61K33/244 ,  C07F7/02 ,  C01B39/46 ,  C01B39/02

摘要： The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

公开(公告)号：US20210052748A1

公开(公告)日：2021-02-25

申请号：US16982856

申请日：2019-03-22

申请人： YONG MIN CHANG ,  HEE KYEONG KIM

发明人： YONG MIN CHANG ,  HEE KYEONG KIM

IPC分类号： A61K49/10 ,  C07D257/02 ,  A61P29/00 ,  A61K33/244

摘要： A compound is disclosed that can be used as an anti-inflammatory agent, a cyclooxygenase-2 inhibitor, a therapeutic agent for brain diseases, or a MRI contrast medium. The compound can have the structure represented by chemical formula 1.

公开(公告)号：US20190328877A1

公开(公告)日：2019-10-31

申请号：US16099108

申请日：2017-05-04

申请人： The Regents of the University of Colorado, a Body Corporate

发明人： William Sauer ,  Duy Nguyen

IPC分类号： A61K41/00 ,  A61B18/02 ,  A61B18/14 ,  A61N2/00 ,  A61K9/127 ,  A61K31/366 ,  A61K49/18 ,  A61K45/06 ,  A61K33/244 ,  A61K33/26 ,  A61P41/00 ,  A61K9/51

摘要： The presently disclosed subject matter provides agents, compositions, and methods for augmenting ablation of a target tissue in a subject in need thereof, for example, using agents that modulate protective and/or reparative cellular processes induced in target tissue by application of ablative energy to the target tissue to sensitize the target tissue to the ablative energy. The presently disclosed subject matter further provides methods for augmenting radiofrequency ablation of cardiac tissue, for example, by applying radiofrequency energy to ablate cardiac tissue in the presence of metallic nanoparticles magnetically guided to the cardiac tissue.

公开(公告)号：US20190298832A1

公开(公告)日：2019-10-03

申请号：US16372492

申请日：2019-04-02

申请人： Hong Kong Baptist University

发明人： Ka Leung WONG ,  Wai Kwok WONG ,  Ho Fai CHAU

IPC分类号： A61K41/00 ,  A61K33/244 ,  A61P35/00 ,  C07F5/00 ,  A61B5/055 ,  G01R33/56

摘要： Provided herein are porphyrinato-lanthanide complexes useful as theranostic agents and methods of preparation and use thereof. The porphyrinato-lanthanide complexes are useful in the treatment and imaging of cancer.

公开(公告)号：US20190262393A1

公开(公告)日：2019-08-29

申请号：US16288694

申请日：2019-02-28

申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

发明人： RUSSELL PESAVENTO

IPC分类号： A61K33/244 ,  A61K9/14

摘要： Described herein are hydrolyzed tetravalent salts and formulations thereof that can be used to inhibit a biofilm. Also described herein are uses of the hydrolyzed tetravalent salts and formulations thereof to inhibit a biofilm and/or treat biofilm infection.